BioCorRx Pharmaceuticals Inc. has acquired LUCEMYRA (lofexidine), a prescription medication designed to mitigate opioid withdrawal symptoms, from USWM, LLC. This strategic acquisition marks a significant milestone in the company's expansion of addiction treatment offerings.
LUCEMYRA represents a critical medical innovation as the first and only FDA-approved non-opioid medication specifically developed to manage opioid withdrawal symptoms. The medication helps patients experiencing acute withdrawal by reducing the neurochemical surge that produces withdrawal effects, potentially making the detoxification process more manageable.
The acquisition is expected to generate meaningful sales and positions LUCEMYRA as a key asset in BioCorRx Pharmaceuticals' product line. By integrating this medication into their portfolio, the company aims to improve access to opioid withdrawal treatment and support patients navigating substance use disorders.
Under the agreement's terms, USWM, LLC will retain a portion of future sales and receive shares of common stock and warrants from BioCorRx Inc. The companies will collaborate to ensure a smooth transition and continued market presence for LUCEMYRA.
The acquisition aligns with BioCorRx's mission to develop innovative, non-opioid treatment solutions for substance abuse. By leveraging their expertise in behavioral health and treatment networks, the company seeks to expand LUCEMYRA's market reach and provide critical support for individuals struggling with opioid withdrawal.
